205 related articles for article (PubMed ID: 8370634)
1. Treatment of postmenopausal osteoporosis with salmon calcitonin nasal spray: evaluation by bone mineral content and biochemical patterns.
Tolino A; Romano L; Ronsini S; Riccio S; Montemagno U
Int J Clin Pharmacol Ther Toxicol; 1993 Jul; 31(7):358-60. PubMed ID: 8370634
[TBL] [Abstract][Full Text] [Related]
2. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
[TBL] [Abstract][Full Text] [Related]
3. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
Overgaard K; Hansen MA; Nielsen VA; Riis BJ; Christiansen C
Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis.
Tekeoğlu I; Adak B; Budancamanak M; Demirel A; Ediz L
Rheumatol Int; 2005 Dec; 26(2):157-61. PubMed ID: 15660234
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
[TBL] [Abstract][Full Text] [Related]
6. Effect of salmon calcitonin nasal spray on bone mass in patients with high turnover osteoporosis.
Gennari C; Agnusdei D; Camporeale A
Osteoporos Int; 1993; 3 Suppl 1():208-10. PubMed ID: 8461563
[No Abstract] [Full Text] [Related]
7. Salmon calcitonin nasal spray treatment for postmenopausal women after hip fracture with total hip arthroplasty.
Peichl P; Marteau R; Griesmacher A; Kumpan W; Schedl R; Prosquil E; Fasol P; Bröll H
J Bone Miner Metab; 2005; 23(3):243-52. PubMed ID: 15838628
[TBL] [Abstract][Full Text] [Related]
8. Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment.
Civitelli R; Gonnelli S; Zacchei F; Bigazzi S; Vattimo A; Avioli LV; Gennari C
J Clin Invest; 1988 Oct; 82(4):1268-74. PubMed ID: 3262626
[TBL] [Abstract][Full Text] [Related]
9. Nasal calcitonin for treatment of established osteoporosis.
Overgaard K; Riis BJ; Christiansen C; Pødenphant J; Johansen JS
Clin Endocrinol (Oxf); 1989 Apr; 30(4):435-42. PubMed ID: 2688995
[TBL] [Abstract][Full Text] [Related]
10. Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers.
Nielsen NM; von der Recke P; Hansen MA; Overgaard K; Christiansen C
Calcif Tissue Int; 1994 Jul; 55(1):8-11. PubMed ID: 7922794
[TBL] [Abstract][Full Text] [Related]
11. Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women.
Mango D; Ricci S; Manna P; Natili G; Dell'Acqua S
Minerva Endocrinol; 1993 Sep; 18(3):115-21. PubMed ID: 8183178
[TBL] [Abstract][Full Text] [Related]
12. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
Overgaard K; Lindsay R; Christiansen C
Clin Ther; 1995; 17(4):680-5. PubMed ID: 8565031
[TBL] [Abstract][Full Text] [Related]
13. Total and regional bone mineral content and fracture rate in postmenopausal osteoporosis treated with salmon calcitonin: a prospective study.
Rico H; Revilla M; Hernández ER; Villa LF; Alvarez de Buergo M
Calcif Tissue Int; 1995 Mar; 56(3):181-5. PubMed ID: 7750020
[TBL] [Abstract][Full Text] [Related]
14. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.
Colpan L; Gur A; Cevik R; Nas K; Sarac AJ
Maturitas; 2005 Jul; 51(3):246-53. PubMed ID: 15978968
[TBL] [Abstract][Full Text] [Related]
15. Long-term (3 years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin.
Reginster JY; Denis D; Deroisy R; Lecart MP; De Longueville M; Zegels B; Sarlet N; Noirfalisse P; Franchimont P
J Bone Miner Res; 1994 Jan; 9(1):69-73. PubMed ID: 8154311
[TBL] [Abstract][Full Text] [Related]
16. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].
Stĕpán J; Formánková J; Masatová A; Michalský M; Rosenová Z
Cas Lek Cesk; 1997 Apr; 136(8):242-8. PubMed ID: 9264868
[TBL] [Abstract][Full Text] [Related]
18. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: the effect of calcium and calcitonin.
Kung AW; Yeung SS
J Clin Endocrinol Metab; 1996 Mar; 81(3):1232-6. PubMed ID: 8772604
[TBL] [Abstract][Full Text] [Related]
19. Salmon calcitonin plus intravaginal estriol: an effective treatment for the menopause.
Melis GB; Cagnacci A; Bruni V; Falsetti L; Jasonni VM; Nappi C; Polatti F; Volpe A
Maturitas; 1996 May; 24(1-2):83-90. PubMed ID: 8794438
[TBL] [Abstract][Full Text] [Related]
20. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
